BR112016014617A2 - Variante do fator xa (fxa) e usos da referida variante - Google Patents

Variante do fator xa (fxa) e usos da referida variante

Info

Publication number
BR112016014617A2
BR112016014617A2 BR112016014617A BR112016014617A BR112016014617A2 BR 112016014617 A2 BR112016014617 A2 BR 112016014617A2 BR 112016014617 A BR112016014617 A BR 112016014617A BR 112016014617 A BR112016014617 A BR 112016014617A BR 112016014617 A2 BR112016014617 A2 BR 112016014617A2
Authority
BR
Brazil
Prior art keywords
variant
fxa
factor
compositions
methods
Prior art date
Application number
BR112016014617A
Other languages
English (en)
Portuguese (pt)
Inventor
Arkin Steven
Fruebis Joachim
E Carr Marcus
Hett Sunita
Jasuja Reema
D Pittman Debra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112016014617A2 publication Critical patent/BR112016014617A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112016014617A 2014-01-24 2015-01-15 Variante do fator xa (fxa) e usos da referida variante BR112016014617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (1)

Publication Number Publication Date
BR112016014617A2 true BR112016014617A2 (pt) 2017-09-19

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016014617A BR112016014617A2 (pt) 2014-01-24 2015-01-15 Variante do fator xa (fxa) e usos da referida variante

Country Status (18)

Country Link
US (2) US20160375109A1 (https=)
EP (1) EP3096779B1 (https=)
JP (1) JP6624787B2 (https=)
KR (3) KR20210008177A (https=)
CN (2) CN112156176A (https=)
AU (1) AU2015208819B2 (https=)
BR (1) BR112016014617A2 (https=)
CA (1) CA2937418A1 (https=)
DK (1) DK3096779T3 (https=)
ES (1) ES2772802T3 (https=)
HU (1) HUE047588T4 (https=)
IL (1) IL246637A0 (https=)
MX (1) MX375355B (https=)
PL (1) PL3096779T3 (https=)
PT (1) PT3096779T (https=)
RU (1) RU2016126423A (https=)
SI (1) SI3096779T1 (https=)
WO (1) WO2015110939A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950813B1 (en) 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005016406D1 (de) * 2004-06-21 2009-10-15 Novo Nordisk Healthcare Ag Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ödemerzeugung nach intrazerebraler hämorrhagie (ich)
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
MX365612B (es) * 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
EP2950813B1 (en) * 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition

Also Published As

Publication number Publication date
EP3096779B1 (en) 2019-12-18
EP3096779A1 (en) 2016-11-30
PT3096779T (pt) 2020-02-21
JP2015147764A (ja) 2015-08-20
WO2015110939A1 (en) 2015-07-30
KR20160093731A (ko) 2016-08-08
MX2016009665A (es) 2016-11-14
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
AU2015208819A1 (en) 2016-06-30
IL246637A0 (en) 2016-08-31
CA2937418A1 (en) 2015-07-30
RU2016126423A3 (https=) 2018-03-01
US20190231856A1 (en) 2019-08-01
DK3096779T3 (da) 2020-02-24
JP6624787B2 (ja) 2019-12-25
ES2772802T3 (es) 2020-07-08
HUE047588T2 (hu) 2020-04-28
AU2015208819B2 (en) 2020-01-23
US20160375109A1 (en) 2016-12-29
CN112156176A (zh) 2021-01-01
MX375355B (es) 2025-03-04
KR20180014221A (ko) 2018-02-07
CN105934250A (zh) 2016-09-07
SI3096779T1 (sl) 2020-03-31
RU2016126423A (ru) 2018-03-01
HUE047588T4 (hu) 2020-06-29

Similar Documents

Publication Publication Date Title
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
IL256684B (en) Medicinal compounds and preparations for the treatment of social disorders and substance use disorders
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
ECSP16075416A (es) Anticuerpos de il-21
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
ZA201702884B (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
DK3129057T3 (da) Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
PL3203998T3 (pl) Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia cukrzycy
SMT202400084T1 (it) Composizione per la prevenzione e/o il trattamento dei sintomi dell’allergia
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
BR112016014617A2 (pt) Variante do fator xa (fxa) e usos da referida variante
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2705 DE 08-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.